| 000 | 01602 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513124600.0 | ||
| 264 | 0 | _c19970918 | |
| 008 | 199709s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(97)00564-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAbernethy, D R | |
| 245 | 0 | 0 |
_aPharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cAug 1997 |
||
| 300 |
_a4C-11C p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBenzimidazoles _xchemistry |
| 650 | 0 | 4 | _aBinding Sites |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xchemistry |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdrug therapy |
| 650 | 0 | 4 | _aControlled Clinical Trials as Topic |
| 650 | 0 | 4 |
_aCoronary Vessels _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHeart Conduction System _xdrug effects |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aMibefradil |
| 650 | 0 | 4 |
_aMuscle, Smooth _xdrug effects |
| 650 | 0 | 4 |
_aRenal Circulation _xdrug effects |
| 650 | 0 | 4 |
_aTetrahydronaphthalenes _xchemistry |
| 650 | 0 | 4 |
_aVascular Resistance _xdrug effects |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 80 _gno. 4B _gp. 4C-11C |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(97)00564-x _zAvailable from publisher's website |
| 999 |
_c9265716 _d9265716 |
||